Phase IV Evaluation of the Adrenal Suppression Potential and PKPD of Halobetasol Propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis

Main Article Content

Adelaide Herbert
Rhonda Schreiber
Debbie Glaab
Lawrence Eichenfeld


halobetasol foam, adrenal suppresion, psoriasis




1. Bronker et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs (2015) 17:373–384. DOI 10.1007/s40272-015-0137-1.

2. Paller et al. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. J Drugs Dermatol. 2018;17(2):187-194.

3. Thomas et al Treating pediatric plaque psoriasis: challenges and solutions. Pediatric Health, Medicine and Therapeutics 2016:7 25–38.

4. Bhatia et al. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis. J Drugs Dermatol. 2019 Aug 1;18(8):790-796.

Most read articles by the same author(s)

1 2 3 > >>